Guillain-Barre Syndrome Two Weeks after 1st Dose of Covid-19
DOI:
https://doi.org/10.47363/qp548k92Keywords:
Guillain-Barre Syndrome, Pfizer COVID-19 vaccine, ataxia, dysmetria, Vaccine Adverse Event Reporting System (VAERS)Abstract
Case Diagnosis: Guillain-Barre Syndrome (GBS) was diagnosed in a female with ataxia, paresthesia, and dysmetria confirmed with CSF analysis.
Case Description: We present a case about a 34-year-old female that developed GBS two weeks after receiving the first dose of the Pfizer COVID-19 vaccine. Setting: The diagnosis was made in the acute hospital, and then treatment continued in the acute rehabilitation setting.
Assessment/Results: Results from the CSF analysis were conclusive with the physical presentation, and the patient was started on the proper treatment protocol, which included IVIG and high-dose steroids. She continually progressed during her rehabilitation period, and an EMG and NCS were scheduled as an outpatient for better confirmation.
Conclusion: It is important to note a patient’s past medical history in the acute rehabilitation setting, including any recent vaccinations. This is because the VAERS requires that all healthcare professionals report adverse events, and all vaccine manufacturers must disclose any adverse events reported to them.
